Antagonists that are competitive, like enzalutamide, were the first‐line treatments for prostate cancer by preventing the transcriptional action of the androgen receptor (Sanford 2013; Watson, Arora, and Sawyers 2015). Here, AR is linked to prostate carcinoma.